Celldex Therapeutics (CLDX) Assets Average (2011 - 2026)

Celldex Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $547.1 million for Q1 2026.

• In Q1 2026, Assets Average fell 28.57% year-over-year to $547.1 million; the TTM figure through Mar 2026 stood at $547.1 million (down 28.57% YoY), while the FY2025 annual figure was $687.7 million, up 9.33% from the prior year.
• Assets Average was $547.1 million for Q1 2026 at Celldex Therapeutics, down from $615.7 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $857.2 million in Q2 2024 to a low of $289.8 million in Q3 2023.
• Historically, Assets Average has averaged $552.3 million across 5 years, with a median of $547.1 million in 2026.
• The sharpest annual moves came in 2024 and 2026: Assets Average surged 187.93% in 2024, then retreated 28.57% in 2026.
• A 5-year view of Assets Average shows it stood at $361.0 million in 2022, then grew by 3.31% to $372.9 million in 2023, then jumped by 116.59% to $807.8 million in 2024, then slipped by 23.78% to $615.7 million in 2025, then dropped by 11.14% to $547.1 million in 2026.
• The last three Assets Average figures came in at $547.1 million (Q1 2026), $615.7 million (Q4 2025), and $670.4 million (Q3 2025), per Business Quant data.